BioSpace News Archive

BioLife Solutions, Inc., announced that Casdin Capital LLC has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second largest shareholder, who has been a primary source of investment capital for the Company since its inception.

Leading authority on genomics and diagnostics in medical practice will help Natera’s efforts in advancing individualized genomic medicine

FDNA, developer of the Face2Gene suite of next-generation phenotyping (NGP) applications, announces at the American College of Medical Genetics and Genomics annual meeting the appointment of Dr. Karen Gripp to Chief Medical Officer and Dr. Peter Krawitz to Chief Data Science Officer.

Additional study sites opened in the U.K. for the 202 Study

Announces Reverse Stock Split and Key Cost-Saving Initiatives

Gilead Sciences Joins Premier Series A Investment Consortium of TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer, and Pfizer

Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has promoted Adam Carie, PhD to Director, Product Development.

Club OS is pleased to announce that it has acquired Lead Dolphin, an innovative CRM for fitness businesses.

Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Stealth’s investigational drug candidate, elamipretide, for the treatment of patients with Barth syndrome.

Joint Program for Clinical Research and Clinical Trial Management to be offered through the PAREXEL Academy